Latest Regulatory Milestones News

Black Cat Syndicate has entered a joint venture with Dreadnought Resources to develop and process ore from the high-grade Star of Mangaroon deposit, aiming to boost production and operational flexibility at its Paulsens facility.

Meteoric Resources NL has had its trading suspension lifted following its response to media speculation about the Preliminary License approval process, reopening investor access to its shares.

Renergen Limited and ASP Isotopes Inc. have secured crucial regulatory approvals and agreed to extend the deadline for completing their Scheme of Arrangement to January 2026, signaling steady progress in their strategic partnership.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Southern Cross Gold has secured approval for its underground exploration tunnel at the Sunday Creek project, marking a pivotal step towards mine development and enhanced resource definition.

SomnoMed Limited reported a robust FY25 with revenue surpassing guidance and a landmark FDA clearance for its Rest Assure® oral device, setting the stage for sustained growth in oral appliance therapy.

Southern Cross Media Group has secured crucial ACMA approval for its proposed merger with Seven West Media, advancing a major consolidation in Australia’s media landscape. The deal now moves closer to final shareholder approval.

Seven West Media has secured crucial approval from the Australian Communications and Media Authority, advancing Southern Cross Media's acquisition plans. The upcoming scheme meeting in December will be pivotal for shareholders.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

Right Resources has confirmed extensive high-grade gold mineralisation along a 1km strike at its Pilot Project in New South Wales, with maiden drilling now in progress to validate these promising findings.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.